# A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

> **NCT07723963** · PHASE2,PHASE3 · RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 260 (estimated)

## Conditions studied

- Juvenile Myoclonic Epilepsy

## Interventions

- **DRUG:** JZP926 capsule
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07723963
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-18
- **Primary completion:** 2028-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723963, "A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07723963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*